Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Sodium Zirconium Cyclosilicate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 484Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AstraZeneca approved to sell hyperkalaemia treatment in India
    AstraZeneca approved to sell hyperkalaemia treatment in India

    08 Mar 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-gets-nod-to-import-sell-hyperkalaemia-treatment-drug-in-india/articleshow/118760930.cms

    ECONOMICTIMES
    08 Mar 2025
    Share Share
    AstraZeneca calls off two late-stage potassium drug trials
    AstraZeneca calls off two late-stage potassium drug trials

    02 Dec 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-scrap-two-trials-drug-that-curbs-potassium-2023-12-01/

    REUTERS
    02 Dec 2023
    Share Share
    LOKELMA Granted FTD by FDA in Chronic Hemodialysis With Hyperkalemia
    LOKELMA Granted FTD by FDA in Chronic Hemodialysis With Hyperkalemia

    17 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211117006015/en

    BUSINESSWIRE
    17 Nov 2021
    Share Share
    Lokelma label update approved in China for patients with hyperkalaemia
    Lokelma label update approved in China for patients with hyperkalaemia

    24 Nov 2020

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-label-update-approved-in-china-for-patients-with-hyperka.html

    PRESS RELEASE
    24 Nov 2020
    Share Share
    EU approves label update for AZ' Lokelma
    EU approves label update for AZ' Lokelma

    04 May 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/eu_approves_label_update_for_az_lokelma_1339580

    Selina McKee PHARMATIMES
    04 May 2020
    Share Share
    Lokelma US label updated to include dosing guidance for hyperkalaemia
    Lokelma US label updated to include dosing guidance for hyperkalaemia

    27 Apr 2020

    // ASTRAZENECA

    https://www.astrazeneca.com/media-centre/medical-releases/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html

    ASTRAZENECA
    27 Apr 2020
    Share Share